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Abstract
In rodents, insufficient adenosine produces behavioral and physiological symptoms consistent
with several comorbidities of autism. In rodents and humans, stimuli postulated to increase
adenosine can ameliorate these comorbidities. Because adenosine is a broad homeostatic
regulator of cell function and nervous system activity, increasing adenosine’s influence might
be a new therapeutic target for autism with multiple beneficial effects.

Introduction
Autism Spectrum Disorder (ASD) and its associated symptomatology have been associated with
abnormalities in several neurotransmitters. The strongest findings involve serotonin, blood
concentrations of which are elevated in many autistic patients (Buitelaar and Willemsen‐
Swinkels, 2000). Other studies or hypotheses have implicated catecholamines (Beversdorf,
2010; Rylander, 1972; Yoo et al., 2009), amino acid transmitters (Fatemi et al., 2009; Purcell et
al., 2001), and peptide transmitters (Bartz and Hollander, 2008). While many mechanisms may
be involved, here we suggest that the neuromodulator adenosine could play a role in
ameliorating neurological and behavioral sequelae of ASD.

A diagnosis of ASD relies on three core behavioral symptoms, irrespective of cognitive function:
deficits in sociability; deficits in communication; and stereotyped and/or repetitive behavior
(American Psychiatric Association, 2000). There is also a constellation of common
comorbidities, including epilepsy, disturbed sleep, anxiety, immune dysfunctions, and
gastrointestinal problems (Landrigan, 2010). The increasing prevalence of ASD is in itself

3

alarming, and it is accompanied by a parallel increase in these chronic comorbidities (Hertz‐
Picciotto et al., 2006; Siegel et al., 2010).

Despite postulated neurochemical abnormalities, and intensive research efforts, at this time
there is no biologically‐validated treatment related directly to core symptoms of autism (Lam et
al., 2006). Treatments are prescribed primarily to limit symptoms (such as seizures or anxiety)
with the hope that reducing co‐morbidities could facilitate general improvements or be
beneficial for core symptoms of the disorder. This frustrating lack of direct medical treatments
for ASD is likely due to a host of factors such as diverse underlying genetic and environmental
interactions, individual differences in the expression of similar underlying genetics and
physiology, and a similar clinical presentation of completely different underlying genetics and
physiology. In addition to these genetic and epigenetic complexities, we may be identifying
non‐essential targets, or producing mixed benefits ‐ symptomatic relief and negative side
effects in parallel.

The plethora of underlying causes – and the range of severity or “spectrum” which exemplifies
ASD ‐ makes it unlikely that a highly specific and targeted therapy will treat a majority of cases.
Rather, ASD may benefit from less selective drugs or interventions that could offer multiple
benefits and fewer serious side effects. This type of approach is consistent with comprehensive
behavioral intervention, currently the most effective treatment for ASD (LeBlanc and Gillis,
2012). Regarding a broad‐based approach with multiple potential benefits, adenosine is a
homeostatic bioenergetic regulator of neuronal activity with diverse short‐ and long‐term
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effects throughout the body (Boison et al., 2011). Adenosine links to metabolism and to
neuronal activity (via ATP/adenine nucleotide pools and actions at G protein‐coupled adenosine
receptors, respectively). It is present throughout the extracellular space, and both neurons and
glia release ATP (which is subsequently dephosphorylated in the extracellular space) or release
adenosine directly (Lovatt et al., 2012). Adenosine is removed from the extracellular space
primarily by equilibrative transport and phosphorylated intracellularly by adenosine kinase
(Dunwiddie and Masino, 2001).

Multiple adenosine receptor agonists are in clinical trials (Gao and Jacobson, 2011), and several
currently approved pharmaceuticals have adenosine‐modulating properties, such as allopurinol
(a xanthine oxidase inhibitor) and dipyridamole (an adenosine transport blocker) (Paterson and
Oliver, 1971; Rundles, 1966). While these agents are not typically prescribed with the intent to
influence adenosine, recent research and clinical trials have explored this mechanism of action
regarding epilepsy (DeMarco and Zagnoni, 1986; Togha et al., 2007; Zagnoni et al., 1994), pain
(Connor, 2009), schizophrenia (Akhondzadeh et al., 2000; Brunstein et al., 2001; Dickerson et
al., 2009; Lara et al., 2001; Weiser et al., 2012), and bipolar disorder (Akhondzadeh et al., 2006;
Fan et al., 2012; Machado‐Vieira et al., 2008). As discussed in more detail below, a ketogenic
diet has also been shown to activate adenosine receptors (Masino et al., 2011b).
Pharmaceutical treatment for children with autism consists primarily of antipsychotics (Posey et
al., 2008); it would seem reasonable to consider therapies with adenosine‐based beneficial
“side effects.”
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Caffeine is a non‐selective adenosine A1/A2 receptor antagonist, and the most widely used
psychoactive drug worldwide (Fredholm et al., 1999). As such, a vast epidemiological database
exists regarding manipulation of adenosinergic activity. Regarding the immediate potential for
adenosine‐based therapies, and in recognition of its safety, accessibility, and neurological
effects, researchers have suggested that caffeine itself may be an adjuvant treatment for
diverse neurological disorders (Ribeiro and Sebastião, 2010), and there is some historical
precedent for this (Fredholm, 2011). As discussed later, caffeine can antagonize adenosine
receptors with acute administration or upregulate adenosine receptor signaling with chronic
administration (Johansson et al., 1997; Li et al., 2008b). Unfortunately, controlled data on
interactions between acute or chronic caffeine and ASD is lacking.

Regarding adenosine modulation and autism, several reports have suggested therapeutic
potential with diverse postulated benefits (Freitag et al., 2010; Ghanizadeh, 2010; Masino et al.,
2009, 2011a; Tanimura et al., 2010). However, at this time the direction of the relationship, the
relevance for particular symptoms, and the receptor subtypes and brain regions involved
remain speculative. Here we explore the relationship between adenosine in the central nervous
system and autism in terms of clinical symptoms, sensory abnormalities and behavior. We also
suggest therapeutic options based on this relationship.

Adenosine and autism – clinical links
Adenosine is known for its role as a sleep‐promoter, a seizure‐reducer, and a neuroprotective
molecule (Dunwiddie and Masino, 2001). All of these roles reflect that adenosine is integral in
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the relationship between metabolism and neuronal activity. For example, increased adenosine
in specific brain areas is thought to promote sleep as a daily homeostatic metabolic response
(Bjorness et al., 2009; Porkka‐Heiskanen and Kalinchuk, 2011; Satoh et al., 1998; Stenberg et al.,
2003). Similarly, during excess neuronal activity or metabolism, increased adenosine provides a
local feedback inhibition which reduces metabolic demand, limits excitability, and protects
neurons from energy failure or excitotoxicity (Fredholm, 2007). We hypothesized that
augmenting adenosine could alleviate core symptoms and some comorbidities of ASD (Masino
et al., 2011a). For instance, adenosine, through A2 receptors (and possibly by coactivation of A1
and A2 receptors), reduces perseverative behaviors in rodents (Poleszak and Manuta, 2000;
Tanimura et al., 2010) and could aid with this core symptom in ASD. In a parental survey‐based
study, conditions and events known to or hypothesized to increase adenosine (e.g. fever, high‐
intensity physical activity, very low carbohydrate diet) significantly improved autistic behaviors,
particularly in Asperger’s and verbally‐fluent individuals (Masino et al., 2011a).

Because caffeine is known to modulate the influence of adenosine, and because it is so widely
used, it is important to consider the interactions and implications of caffeine use in individuals
with ASD. Hypotheses regarding adenosine’s influence on symptoms of autism suggest that
chronic rather than acute caffeine might be most helpful for treating some symptoms and
comorbidities. While acute caffeine ‐ at doses ingested typically by humans – transiently blocks
a portion of brain adenosine A1 and A2 receptors, multiple research reports show that chronic
caffeine upregulates the influence of adenosine A1 receptors somewhat selectively (Green and
Stiles, 1986; Li et al., 2008b; Rudolphi et al., 1989) ‐ although not all findings concur on this
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point (Johansson et al., 1997). Beyond direct neural effects, there may be an important
influence of increased adenosine A1 receptor activation on microglia and immune function
(Chen et al., 2010; Tsutsui et al., 2004). Thus, save for the time period when the acute dose of
caffeine is active, the net effect may be increased adenosine A1 receptor activation. This
outcome should be considered with respect to epilepsy therapy given the incontrovertible role
of the adenosine A1 receptor as an anticonvulsant mechanism. In contrast, chronic caffeine may
have less of an influence on adenosine A2A receptor regulation (Li et al., 2008b; Lupica et al.,
1991), suggesting a continuation of acute effects even with chronic use. The influence of
caffeine on adenosine receptors, and the timing, frequency and dose of caffeine use, should be
considered with respect to any adenosine‐modulating therapy.

Regarding comorbidities, anxiety is a prominent comorbidity in ASD (White et al., 2009), and
increased adenosine is anxiolytic (Jain et al., 1995). As for seizures, the evidence that adenosine
can decrease or stop them is overwhelming (for instance, Etherington and Frenguelli, 2004; Ilie
et al., 2012), and the high prevalence of seizures in children with autism is well‐established
(Seidenberg et al., 2009; Tuchman and Rapin, 2002). The reported rate of co‐morbid seizures in
ASD (estimates range from 5‐40%) is inevitably conservative: in the absence of behavioral
evidence, electroencephalographic (EEG) recordings are not performed routinely in ASD. In
addition to the possibility of undetected EEG abnormalities there remains the likelihood that
subcortical or localized abnormal EEG activity or microseizures may be occurring, also without
any behavioral indication, and such events may be undetectable with surface electrodes. For
example, these types of non‐behavioral seizures observed only with implanted electrodes have
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been observed in several mouse models of adenosine deficiency and Alzheimer’s disease (Li et
al., 2008a; Masino et al., 2011b; Palop et al., 2007). Regardless of the cause of frank seizures or
covert seizure activity, increasing adenosine would be predicted to be an effective strategy in
mitigating this abnormal activity.

More recently, diverse neurological disorders such as Parkinson’s disease, schizophrenia and
chronic pain have been linked to or noted as treated by adenosine‐based mechanisms
(Burnstock et al., 2011). Increased adenosine is analgesic (Herrick‐Davis et al., 1989; Jain et al.,
1995) whereas decreased adenosine causes hyperalgesia (Johansson et al., 2001). Regarding
schizophrenia and ASD, schizophrenia has recently been postulated to be an adult‐onset type of
autism. This comparison is due to a number of commonalities including gray matter reductions
in a partially overlapping set of regions (Cheung et al., 2010), and similar deficits in brain
connectivity, mirror neuron function, and theory of mind (King and Lord, 2011). In parallel, over
the last decade an adenosine hypothesis of schizophrenia has been evolving, in which abnormal
adenosine levels allow overactivity of dopaminergic systems (leading to positive symptoms, e.g.
hallucinations) and underactivity of glutamatergic systems (leading to negative symptoms, e.g.
social withdrawal) (Boison et al., 2012; Lara and Souza, 2000). Recently, adenosine‐releasing
grafts were shown to reverse behavioral and cognitive impairments in an anatomically specific
manner in a mouse model of schizophrenia (Shen et al., 2012). These results linking adenosine
and schizophrenia may have implications for ASD and more work is needed.

Adenosine and autism – sensory abnormalities
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Sensory abnormalities are common in ASD, and persons with autism report these as the most
distressing aspects of their disorder (Grandin, 2009). There have been multiple studies which
show that children on the autism spectrum not only suffer from sensory abnormalities, but are
more likely to suffer from more than one of these abnormalities compared to other children
with developmental and language disabilities (Kientz and Dunn, 1996; Leekam et al., 2007).
These abnormalities can manifest in children with ASD being either over‐ or under‐reactive to
sensory input. In a study of 37 children with autism, it was found that 13 displayed sensory
defensiveness as part of their pathology (Kern et al., 2001). Sensory defensiveness is defined as
a low threshold for sensory input, and results in avoidant behaviors and adverse reactions to
seemingly innocuous environmental occurrences or contact (Kern et al., 2006). As a result,
clothes and their tags can be uncomfortable and certain textures or tastes of foods are avoided
and can lead to a severely restricted diet. In addition, bright lights are disturbing, and various
noises, many noises and loud noises are abnormally distressing to someone suffering from a
low sensory threshold (Kern et al., 2001).

In a study conducted by Rosenhall et al. (1999), autistic children were compared to controls in
auditory processing, and 18% of the autistic participants were found to be especially sensitive
to sounds, a stark contrast to the controls where none were found to have abnormal
perception (n=199). Another study found that every autistic child under age three had auditory
sensory abnormalities compared to a control group (n = 26; Dahlgren and Gillberg, 1989).
Finally, in a comprehensive study conducted on 104 autistic children and matched controls, it
was found that the autistic participants had abnormal auditory, oral, tactile and visual sensory
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processing; the younger the subject, the more pronounced the abnormalities based on scores
on the Sensory Profile (Kern et al., 2006). Behaviors that may develop to adapt to or cope with
hyper‐ and hypo‐sensitive processing common in ASD are potentially maladaptive.

With respect to adenosine and sensory processing, research has shown that adenosine
disruption or augmentation is associated with specific sensory effects. For example, the shake
reflex in rats, elicited by immersion in ice water or injection of icilin, was suppressed by an
injection of adenosine or 2‐chloroadenosine, a metabolically stable adenosine analogue (Tse
and Wei, 1986). This result suggests that adenosine plays a role in inhibiting somatosensory
processing, which then causes changes in behavior. In mice, a spinal injection of adenosine was
shown to have antinociceptive effects, and receptor antagonists induced a pain response,
supporting the hypothesis that adenosine plays a role in inhibiting sensory perception (Keil and
DeLander, 1996). Consistent with this, allopurinol was shown to reduce pain via increasing the
actions of adenosine at the A1 receptor subtype (Schmidt et al., 2009).

Adenosine influences sensory processing in other systems as well. In the auditory system
adenosine receptors are found in cochlear tissues, and adenosine A1 receptor expression in the
cochlea has been shown to increase under auditory stress, perhaps serving a protective role
(Ramkumar et al., 2004; Vlajkovic et al., 2007). In the visual system, adenosine suppresses
exocytosis in retinal cone terminals by decreasing Ca2+ channel activity, thus reducing light
transduction, and is neuroprotective for both cones and rods (Stella et al., 2010).
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Together, these studies indicate that augmentation of adenosine can reduce sensory sensitivity,
and a deficiency in adenosine levels or receptors could result in altered thresholds of sensitivity
in sensory processing for at least touch, vision and hearing. Combined with the profuse
evidence of the presence of sensory abnormalities experienced in individuals on the autism
spectrum, adenosine augmentation emerges as a strong candidate for the investigation into the
treatment of these symptoms.

Adenosine and autism ‐ metabolic therapy
Metabolic therapies include pharmacological and/or physiological strategies, and dietary
treatments and/or supplements. Dietary treatments for ASD are many, but few offer either
controlled clinical studies or clear evidence of efficacy. Despite this, dietary approaches remain
popular with parents, who currently have no safe and effective pharmacological option to
address core symptoms. Even though there is little evidence that these diets are specifically
helping with symptom of autism, evidence is mounting consistently that a whole food diet is
associated with less depression and anxiety and a general sense of well‐being. In contrast, a
poor diet was associated with negative mental health outcomes such as depression and anxiety
(Jacka et al., 2010, 2011; Sánchez‐Villegas et al., 2011). These recent findings include large
prospective studies, both genders, and adolescents and adults. Therefore, a healthy diet would
seem to be helpful mentally and physically, and could complement other therapeutic
interventions.
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Regarding evidence‐based medicine, historically fasting was a metabolic treatment for a wide
variety of illnesses and ailments (Kerndt et al., 1982), and epilepsy provides an example of a
clear relationship between fasting and brain function. Fasting can stop seizures, but the
necessary termination of the fast often precipitated a seizure shortly thereafter (Wheless,
2008). These observations of the relationship between fasting and seizures were validated
subsequently by a metabolic therapy using a dietary approach. A ketogenic diet is a high fat,
low carbohydrate, adequate protein formula which, similar to fasting, promotes the use of
ketones (rather than glucose) for energy. This dietary protocol has been validated as effective
as stopping seizures in retrospective, prospective, multi‐center, and randomized studies
(Hassan et al., 1999; Neal et al., 2008; Vining et al., 1998). The ketogenic diet has been in use
for over 90 years, and even the earliest reports noted dramatic efficacy in refractory seizures in
children and adults, and also noted anti‐seizure effects that outlasted the administration of the
diet itself – suggesting long‐term disease modification (Wilder, 1921a, b).

In current clinical practice there is continuing evidence for lasting changes – children can be on
the diet for 6 months to 2 years, gradually weaned off the diet and often have no ongoing
dietary restrictions and remain seizure‐free (Martinez et al., 2007). In a prospective study,
children who were randomly assigned the ketogenic diet experienced fewer seizures (and some
became seizure‐free) whereas children who continued with the current standard of care with
antiepileptic drugs gradually become worse ‐ experienced increased seizures over time, and
none became seizure‐free (Neal et al., 2008). If long term improvement or recovery (similar to
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epilepsy) could be mobilized for autism ‐ either with a metabolic dietary approach or an
analogous pharmacotherapy, it would address a major treatment gap.

Recently it was shown that a KD increases the actions of adenosine at adenosine A1 receptors
to stop electrographic seizures (Masino et al., 2011b), and an in vitro mimic of the ketogenic
diet similarly revealed adenosine‐based neuronal inhibition (Kawamura et al., 2010). A key
aspect of this in vitro mimic is sufficient intracellular ATP and reduced extracellular glucose, two
metabolic features of the ketogenic diet. A separate study in hippocampal slices demonstrated
an analogous finding: supplementing artificial CSF with d‐ribose and adenine increased adenine
nucleotide levels and increased extracellular adenosine sufficient to alter activity‐dependent
long‐term potentiation in hippocampal slices and influenced synaptic plasticity (zur Nedden et
al., 2011). A survey of parents of children with autism showed that stimuli postulated to
increase adenosine can ameliorate symptoms of autism (Masino et al., 2011a). These studies
suggest that diverse metabolic approaches can reliably increase adenosine signaling.

Although the advent of antiepileptic pharmaceuticals diminished general interest in dietary
therapy, ketogenic diets remain an important option for pediatric and refractory epilepsy.
Their particular success with pediatric epilepsy, and long term outcomes, make the diet an
option that should seriously be considered in conditions where seizures are co‐morbid, such as
autism. Due to multiple confounding factors, treatment‐resistant epilepsy in autism is
associated with very poor outcomes (Sansa et al., 2011).
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Currently, there are few studies regarding the effects of the KD on autistic behavior. There has
been only one prospective study of the effects of an intermittent ketogenic diet on the
behavior of children with autism (Evangeliou et al., 2003). This pilot study was conducted on 30
children four to ten years old. The diet was applied intermittently for six months and parents
were asked to evaluate their child’s behavior using the Childhood Autism Rating Scale. Of the
group that maintained the diet (18 of 30 children = 60%), two children reported a significant
improvement (>12 units on the scale), eight patients an average improvement (8‐12 units) and
eight children a mild improvement (2‐8 units). The biggest improvements were noticed in those
patients who showed only mild autistic behavior. Nevertheless, these results are promising.

In a pilot study of seven girls with Rett syndrome (which primarily affects girls and presents
with dementia, repetitive hand movements, a lack of speech, and severe seizures), parental
reports revealed that the diet caused small improvements in behavior, sociability, and mood in
five out of seven subjects (Haas et al., 1986), suggesting behavioral improvements that would
be beneficial for ASD. In agreement with this clinical finding, a study by Mantis et al. (2009)
described ketogenic diet‐induced improvements in emotional withdrawal, hesitance, and
anxiety in the MeCP2308/y mouse model of Rett syndrome. However, as the study included a
standard diet‐restricted group with similar behavioral improvements, the authors concluded
that the neuroprotective effects stemmed primarily from a reduction in total calorie intake
rather than caloric origin. Other effects of the KD do not rely on caloric restriction, however
(Ruskin et al., 2009). More research is needed in this area.
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Of clinical importance considering the high comorbidity of autism and epilepsy, significant
autistic behaviors in a naturalistic mouse model of epilepsy (the EL mouse) have been
quantified (Meidenbauer et al., 2011). Previously, seizures in this model was shown to be
reduced by a calorically‐restricted standard or ketogenic diet (Mantis et al., 2004), and their
onset delayed by a ketogenic diet (Todorova et al., 2000). Recently we found that a ketogenic
diet reduced autistic behaviors in in the BTBR T+ tf/J mouse, a non‐epileptic model of autism
(Masino et al., 2012). These and other models may provide new platforms to test hypotheses
and therapies that target core symptoms of autism.

Overall, metabolic approaches to treating neurological disorders are gaining credibility for
several reasons: (1) metabolic dysfunction is found with neurological dysfunction, although is it
typically unclear which came first; (2) the neurological dysfunction associated with epilepsy has
been proven to be treated with metabolic therapy; (3) data are emerging regarding the ability
of a ketogenic diet to treat other acute and chronic disorders beyond epilepsy (spinal cord
injury, neurodegenerative disorders). Autism could benefit significantly from hypothesis‐based
metabolic approaches.

Conclusions
Basic and clinical research suggests a meaningful relationship between adenosine and treating
ASD. The nature of that relationship deserves more research. Meanwhile, the prevalence of
autism diagnoses has been increasing at an alarming rate ‐ far outpacing increases in any other
developmental disorder (Centers for Disease Control and Prevention, 2012) ‐ and the source of
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this continued increase is not well understood. Regardless of the cause, new treatments are
needed.

Taken together, emerging evidence suggests that pursuing a hypothesis‐based, evidence‐based
rationale regarding the potential for adenosine‐modulating therapies for autism is ready for
clinical implementation. For patients with refractory epilepsy, a ketogenic diet might offer
multiple benefits. For adult patients with autism, currently approved drugs could be tested
immediately, and other options may soon be on the horizon.
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